(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
, | ||||
(Address of principal executive offices) | (Zip Code) | |||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||
Large accelerated filer | ☐ | ☒ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ||
Emerging growth company | ||||
i | 2025 FORM 10-K | ||
Item 1. | |||
Item 1A. | |||
Item 1B. | |||
Item 1C. | Cybersecurity | ||
Item 2. | |||
Item 3. | |||
Item 4. | |||
Item 5. | |||
Item 6. | Reserved | ||
Item 7. | |||
Item 7A. | |||
Item 8. | |||
Item 9. | |||
Item 9A. | |||
Item 9B. | |||
Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | ||
Item 10. | |||
Item 11. | |||
Item 12. | |||
Item 13. | |||
Item 14. | |||
Item 15. | |||
Item 16. | |||
2 | 2025 FORM 10-K | FORWARD-LOOKING STATEMENTS | |
3 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
4 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
5 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
6 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
7 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
8 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
9 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
10 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
11 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
12 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
13 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
14 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
15 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
16 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
17 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
18 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
19 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
20 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
21 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
22 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
23 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
24 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
25 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
26 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
27 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
28 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
29 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
30 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
31 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
32 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Retail Stores | Retail Stores | Retail Stores | |||||
Alabama | 9 | Louisiana | 10 | Ohio | 20 | ||
Alaska | 1 | Maine | 3 | Oklahoma | 5 | ||
Arizona | 14 | Maryland | 14 | Oregon | 8 | ||
Arkansas | 7 | Massachusetts | 9 | Pennsylvania | 24 | ||
California | 62 | Michigan | 19 | Rhode Island | 1 | ||
Colorado | 15 | Minnesota | 14 | South Carolina | 10 | ||
Connecticut | 6 | Mississippi | 5 | South Dakota | 2 | ||
Delaware | 2 | Missouri | 12 | Tennessee | 14 | ||
Florida | 44 | Montana | 4 | Texas | 54 | ||
Georgia | 20 | Nebraska | 4 | Utah | 6 | ||
Hawaii | 2 | Nevada | 6 | Vermont | 1 | ||
Idaho | 3 | New Hampshire | 4 | Virginia | 18 | ||
Illinois | 23 | New Jersey | 14 | Washington | 17 | ||
Indiana | 14 | New Mexico | 4 | West Virginia | 3 | ||
Iowa | 6 | New York | 19 | Wisconsin | 11 | ||
Kansas | 5 | North Carolina | 20 | Wyoming | 2 | ||
Kentucky | 8 | North Dakota | 2 | ||||
Total | 600 |
33 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
34 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Period | Total Number of Shares Purchased(1)(2) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(3) | ||||
September 28, 2025 through October 25, 2025 | 523 | $6.94 | — | $348,071,000 | ||||
October 26, 2025 through November 29, 2025 | 34,617 | $5.27 | — | 348,071,000 | ||||
November 30, 2025 through January 3, 2026 | 1,560 | $8.32 | — | 348,071,000 | ||||
Total | 36,700 | $5.43 | — | $348,071,000 |
35 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |

12/28/19 | 01/01/22 | 12/31/22 | 12/30/23 | 12/28/24 | 01/03/26 | |
Sleep Number Corporation | $100 | $94 | $32 | $18 | $19 | $10 |
S&P 400 Specialty Stores Index | $100 | $146 | $136 | $167 | $164 | $159 |
The Nasdaq Stock Market (U.S.) Index | $100 | $122 | $82 | $117 | $154 | $181 |
36 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
37 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
38 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
39 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | 2023 | |||||||||
$ | % of Net Sales | $ | % of Net Sales | $ | % of Net Sales | ||||||
Net sales | $1,411.5 | 100.0% | $1,682.3 | 100.0 % | $1,887.5 | 100.0% | |||||
Cost of sales | 578.5 | 41.0% | 679.5 | 40.4 % | 799.0 | 42.3% | |||||
Gross profit | 833.0 | 59.0% | 1,002.8 | 59.6 % | 1,088.5 | 57.7% | |||||
Operating expenses: | |||||||||||
Sales and marketing | 664.2 | 47.1% | 766.6 | 45.6 % | 847.4 | 44.9% | |||||
General and administrative | 130.7 | 9.3% | 150.0 | 8.9 % | 146.6 | 7.8% | |||||
Research and development | 33.9 | 2.4% | 45.3 | 2.7 % | 55.8 | 3.0% | |||||
Restructuring costs | 50.7 | 3.6% | 18.1 | 1.1 % | 15.7 | 0.8% | |||||
Total operating expenses | 879.5 | 62.3% | 979.9 | 58.2 % | 1,065.6 | 56.5% | |||||
Operating (loss) income | (46.6) | (3.3%) | 22.9 | 1.4 % | 22.9 | 1.2% | |||||
Interest expense, net | 49.4 | 3.5% | 48.4 | 2.9 % | 42.7 | 2.3% | |||||
Loss before income taxes | (96.0) | (6.8%) | (25.5) | (1.5 %) | (19.8) | (1.0)% | |||||
Income tax expense (benefit) | 36.0 | 2.5% | (5.2) | (0.3 %) | (4.5) | (0.2)% | |||||
Net loss | $(132.0) | (9.3%) | $(20.3) | (1.2 %) | $(15.3) | (0.8)% | |||||
Net loss per share: | |||||||||||
Basic and diluted | $(5.77) | $(0.90) | $(0.68) | ||||||||
Weighted-average number of common shares: | |||||||||||
Basic and diluted | 22.9 | 22.6 | 22.4 | ||||||||
2025 | 2024 | 2023 | |||
Retail stores | 87.6% | 87.6% | 86.8% | ||
Online, phone, chat and other | 12.4% | 12.4% | 13.2% | ||
Total Company | 100.0% | 100.0% | 100.0% |
Net Sales Increase/(Decrease) | |||||
2025 | 2024 | 2023 | |||
Retail comparable-store sales(1) | (17%) | (9%) | (12%) | ||
Online, phone and chat(1) | (17%) | (17%) | (15%) | ||
Total Retail comparable sales change(1) | (17%) | (10%) | (12%) | ||
Net opened/closed stores and 53rd week | 1% | (1%) | 1% | ||
Total Company | (16%) | (11%) | (11%) | ||
40 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | 2023 | |||
Average sales per store ($ in thousands)(1)(4) | $1,946 | $2,601 | $2,853 | ||
Average sales per square foot(1)(4) | $629 | $841 | $926 | ||
Stores > $2 million in net sales(2)(4) | 32% | 57% | 65% | ||
Stores > $3 million in net sales(2)(4) | 8% | 18% | 24% | ||
Average revenue per smart bed unit – Total Retail(3) | $6,060 | $5,818 | $5,755 |
2025 | 2024 | 2023 | |||
Beginning of period | 640 | 672 | 670 | ||
Opened | 6 | 12 | 36 | ||
Closed | (46) | (44) | (34) | ||
End of period | 600 | 640 | 672 |
41 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
42 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
43 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | ||
Total cash provided by (used in): | |||
Operating activities | $(3,283) | $27,143 | |
Investing activities | (17,687) | (26,291) | |
Financing activities | 20,713 | (1,441) | |
Net decrease in cash and cash equivalents | $(257) | $(589) |
44 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Year | ||||||
2025 | 2024 | 2023 | ||||
Net loss | $(131,958) | $(20,334) | $(15,287) | |||
Income tax expense (benefit) | 35,984 | (5,162) | (4,466) | |||
Interest expense | 49,382 | 48,368 | 42,695 | |||
Depreciation and amortization | 53,169 | 64,979 | 72,479 | |||
Stock-based compensation | 6,282 | 11,444 | 14,855 | |||
Restructuring costs(1) | 50,697 | 18,066 | 15,728 | |||
Other non-recurring items(2) | 14,699 | 998 | — | |||
Asset impairments | — | 1,220 | 672 | |||
Adjusted EBITDA | $78,255 | $119,579 | $126,676 | |||
45 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Year | ||||
2025 | 2024 | |||
Inventory obsolescence write off | $9,565 | $— | ||
CEO transition costs | 1,584 | 224 | ||
Debt issuance cost write off | 1,596 | — | ||
Proxy contest costs | 1,148 | 774 | ||
CFO search costs | 340 | — | ||
Legal and consulting costs | 466 | |||
Other non-recurring items | $14,699 | $998 | ||
Year | |||||
2025 | 2024 | 2023 | |||
Net cash (used in) provided by operating activities | $(3,283) | $27,143 | $(9,028) | ||
Subtract: Purchases of property and equipment | (14,407) | (23,505) | (57,056) | ||
Free cash flow | $(17,690) | $3,638 | $(66,084) | ||
Year | |||
2025 | 2024 | ||
Operating expenses | $879,543 | $979,901 | |
Subtract: Restructuring costs | 50,697 | 18,066 | |
Subtract: Other non-recurring items(1) | 5,134 | 998 | |
Non-GAAP operating expenses | $823,712 | $960,837 | |
Operating expense reduction versus prior period, excluding restructuring costs and non-recurring items | $137,125 | ||
46 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Year | |||||
2025 | 2024 | 2023 | |||
Adjusted net operating profit after taxes (Adjusted NOPAT) | |||||
Operating (loss) income | $(46,592) | $22,872 | $22,942 | ||
Add: Operating lease interest(1) | 24,346 | 26,775 | 27,777 | ||
Add/Less: Income taxes(2) | 4,495 | (11,907) | (11,851) | ||
Adjusted NOPAT | $(17,751) | $37,740 | $38,868 | ||
Average adjusted invested capital | |||||
Total deficit | $(578,475) | $(451,586) | $(441,928) | ||
Add: Long-term debt(3) | 588,359 | 546,841 | 539,819 | ||
Add: Operating lease obligations(4) | 354,302 | 389,508 | 433,154 | ||
Total adjusted invested capital at end of period | $364,186 | $484,763 | $531,045 | ||
Average adjusted invested capital(5) | $439,902 | $497,972 | $496,612 | ||
Adjusted return on invested capital (Adjusted ROIC) | (4.0)% | 7.6% | 7.8% | ||
47 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Description | Judgments and Uncertainties | Effect if Actual Results Differ from Assumptions | ||
Stock-Based Compensation | ||||
The Company has stock-based compensation plans, which include non- qualified stock options and stock awards. See Note 1, Business and Summary of Significant Accounting Policies, and Note 8, Shareholders’ Deficit, to the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K, for a complete discussion of its stock-based compensation programs. | Option-pricing models and generally accepted valuation techniques require management to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the volatility of its stock price, future employee forfeiture rates and future employee stock option exercise behaviors. Changes in these assumptions can materially affect the fair value estimates or future earnings adjustments. Performance-based stock awards require management to make assumptions regarding the likelihood of achieving performance targets. | The Company does not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions it uses to determine stock-based compensation expense. However, if actual results are not consistent with its estimates or assumptions, the Company may be exposed to changes in stock-based compensation expense that could be material. In addition, if actual results are not consistent with the assumptions used, the stock-based compensation expense reported in its financial statements may not be representative of the actual economic cost of the stock-based compensation. Finally, if the actual forfeiture rates, or the actual achievement of performance targets, are not consistent with the assumptions used, the Company could experience future earnings adjustments. A 10% change in its stock-based compensation expense for the year ended January 3, 2026, would have affected net loss by approximately $0.5 million in 2025. | ||
48 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Description | Judgments and Uncertainties | Effect if Actual Results Differ from Assumptions | ||
Warranty Liabilities | ||||
The Company provides a limited warranty on most of the products it sells. See Note 1, Business and Summary of Significant Accounting Policies, to the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K, for a complete discussion of its warranty program and liabilities. | The majority of its warranty claims are incurred within the first year. However, the Company’s warranty liability contains uncertainties because its warranty obligations cover an extended period of time. A revision of estimated claim rates or the projected cost of materials and freight associated with sending replacement parts to customers could have a material adverse effect on future results of operations. | The Company has not made any material changes in its warranty liability assessment methodology during the past three fiscal years. The Company does not believe there is a reasonable likelihood that there will be a material change in the estimates or assumptions it uses to calculate its warranty liability. However, if actual results are not consistent with its estimates or assumptions, the Company may be exposed to losses or gains that could be material. A 10% change in its warranty liability at January 3, 2026, would have affected net loss by approximately $0.5 million in 2025. | ||
Revenue Recognition | ||||
Certain accounting estimates relating to revenue recognition contain uncertainty because they require management to make assumptions and to apply judgment regarding the effects of future events. See Note 1, Business and Summary of Significant Accounting Policies, and Note 9, Revenue Recognition, to the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K, for a complete discussion of its revenue recognition policies. | The Company’s estimates of sales returns contain uncertainties as actual sales return rates may vary from expected rates, resulting in adjustments to net sales in future periods. These adjustments could have an adverse effect on future results of operations. | The Company has not made any material changes in the accounting methodology used to establish its sales returns allowance during the past three fiscal years. The Company does not believe there is a reasonable likelihood that there will be a material change in the estimates or assumptions it uses to calculate its sales returns allowance. However, if actual results are not consistent with its estimates or assumptions, the Company may be exposed to additional losses or gains in future periods. A 10% change in its sales returns allowance at January 3, 2026 would have affected net loss by approximately $1.0 million in 2025. | ||
Valuation Allowance for Deferred Tax Assets | ||||
The Company records a reduction to the carrying amounts of deferred tax assets by recording a valuation allowance if, based on the available evidence, it is more likely than not such assets will not be realized. See Note 1, Business and Summary of Significant Accounting Policies, and Note 12, Income Taxes, to the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K, for a complete discussion of its income taxes policies. | The Company considers both positive and negative evidence when measuring the need for a valuation allowance. The weight given to the evidence is commensurate with the extent to which it may be objectively verified. Current and cumulative financial reporting results are a source of objectively verifiable information. We give operating results during the most recent three-year period a significant weight in our analysis. We perform scheduling exercises to determine if sufficient taxable income of the appropriate character exists in the periods required in order to realize our deferred tax assets with limited lives prior to their expiration. | On the basis of the Company’s evaluation, as of January 3, 2026, a valuation allowance of $55.3 million has been recorded to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if additional objectively verifiable positive evidence materializes in future reporting periods, such as a demonstrated operating profitability. | ||
49 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
50 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
51 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
52 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
53 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
54 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ | $ | |
Accounts receivable, net of allowances of $ | |||
Inventories | |||
Prepaid expenses | |||
Other current assets | |||
Total current assets | |||
Non-current assets: | |||
Property and equipment, net | |||
Operating lease right-of-use assets | |||
Goodwill and intangible assets, net | |||
Deferred income taxes | |||
Other non-current assets | |||
Total assets | $ | $ | |
Liabilities and Shareholders’ Deficit | |||
Current liabilities: | |||
Borrowings under revolving credit facility | $ | $ | |
Accounts payable | |||
Customer prepayments | |||
Accrued sales returns | |||
Compensation and benefits | |||
Taxes and withholding | |||
Operating lease liabilities | |||
Other current liabilities | |||
Total current liabilities | |||
Non-current liabilities: | |||
Operating lease liabilities | |||
Other non-current liabilities | |||
Total liabilities | |||
Shareholders’ deficit: | |||
Undesignated preferred stock; outstanding | |||
Common stock, $ shares issued and outstanding, respectively | |||
Additional paid-in capital | |||
Accumulated deficit | ( | ( | |
Total shareholders’ deficit | ( | ( | |
Total liabilities and shareholders’ deficit | $ | $ |
55 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | 2023 | |||
Net sales | $ | $ | $ | ||
Cost of sales | |||||
Gross profit | |||||
Operating expenses: | |||||
Sales and marketing | |||||
General and administrative | |||||
Research and development | |||||
Restructuring costs | |||||
Total operating expenses | |||||
Operating (loss) income | ( | ||||
Interest expense, net | |||||
Loss before income taxes | ( | ( | ( | ||
Income tax expense (benefit) | ( | ( | |||
Net loss | $( | $( | $( | ||
Basic and diluted net loss per share: | |||||
Net loss per share – basic and diluted | $( | $( | $( | ||
Weighted-average shares – basic and diluted |
56 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Common Stock | Additional Paid-in Capital | Accumulate d Deficit | |||||||
Shares | Amount | Total | |||||||
Balance at December 31, 2022 | $ | $ | $( | $( | |||||
Net loss | — | — | — | ( | ( | ||||
Exercise of common stock options | — | ||||||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | ( | ( | ( | |||||
Balance at December 30, 2023 | $ | $ | $( | $( | |||||
Net loss | — | — | — | ( | ( | ||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | ( | ( | ( | |||||
Balance at December 28, 2024 | $ | $ | $( | $( | |||||
Net loss | — | — | — | ( | ( | ||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | ( | ( | — | ( | ||||
Balance at January 3, 2026 | $ | $ | $( | $( | |||||
57 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | 2023 | |||
Cash flows from operating activities: | |||||
Net loss | $( | $( | $( | ||
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||
Depreciation and amortization | |||||
Stock-based compensation | |||||
Inventory obsolescence write off | |||||
Loss on impairment of strategic investment asset | |||||
Loss on disposal and impairment of leased assets | |||||
Deferred income taxes | ( | ( | |||
Changes in operating assets and liabilities: | |||||
Accounts receivable | ( | ||||
Inventories | ( | ||||
Income taxes | ( | ( | |||
Prepaid expenses and other assets | ( | ( | |||
Accounts payable | ( | ( | |||
Customer prepayments | ( | ( | ( | ||
Accrued compensation and benefits | ( | ( | |||
Other taxes and withholding | ( | ( | ( | ||
Other accruals and liabilities | ( | ( | ( | ||
Net cash (used in) provided by operating activities | ( | ( | |||
Cash flows from investing activities: | |||||
Purchases of property and equipment | ( | ( | ( | ||
Proceeds from sales of property and equipment | |||||
Issuance of notes receivable | ( | ( | |||
Payment to secure contractual rights | ( | ||||
Net cash used in investing activities | ( | ( | ( | ||
Cash flows from financing activities: | |||||
Net increase (decrease) in short-term borrowings | ( | ||||
Repurchases of common stock | ( | ( | ( | ||
Proceeds from issuance of common stock | |||||
Debt issuance costs | ( | ( | |||
Net cash provided by (used in) financing activities | ( | ||||
Net (decrease) increase in cash and cash equivalents | ( | ( | |||
Cash and cash equivalents, at beginning of period | |||||
Cash and cash equivalents, at end of period | $ | $ | $ | ||
Supplemental Disclosure of Cash Flow Information | |||||
Income taxes paid, net of refunds | $ | $ | $ | ||
Interest paid | $ | $ | $ | ||
Purchases of property and equipment included in accounts payable | $ | $ | $ |
58 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
59 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Leasehold improvements | |
Furniture and equipment | |
Production machinery | |
Computer equipment and software |
60 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | 2023 | |||
Balance at beginning of period | $ | $ | $ | ||
Additions charged to costs and expenses for current-year sales | |||||
Deductions from reserves | ( | ( | ( | ||
Change in liabilities for pre-existing warranties during the current year, including expirations | ( | ( | |||
Balance at end of period | $ | $ | $ |
61 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
62 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Cost of Sales | Sales & Marketing | |||
• | Costs associated with purchasing, manufacturing, shipping, handling and delivering the Company’s products to its retail stores and customers, including payroll and benefits; | • | Advertising, marketing and media production; | |
• | Marketing and selling materials such as brochures, videos, websites, customer mailings and in-store signage; | |||
• | Physical inventory losses, scrap and obsolescence; | • | Payroll and benefits for sales and customer service staff; | |
• | Purchase commitment obsolescence; | • | Store occupancy costs; | |
• | Related occupancy and depreciation expenses; | • | Store depreciation expense; | |
• | Costs associated with returns and exchanges; and | • | Credit card processing fees; and | |
• | Estimated costs to service customer warranty claims. | • | Promotional financing costs. | |
G&A | R&D(1) | |||
• | Payroll and benefit costs for corporate employees, including information technology, legal, human resources, finance, sales and marketing administration, investor relations and risk management; | • | Internal labor and benefits related to research and development activities; | |
• | Outside consulting services related to research and development activities; and | |||
• | Occupancy costs of corporate facilities; | • | Testing equipment related to research and development | |
• | Depreciation related to corporate assets; | ___________________________ (1) Costs incurred in connection with R&D are charged to expense as incurred. | ||
• | Information hardware, software and maintenance; | |||
• | Insurance; | |||
• | Investor relations costs; and | |||
• | Other overhead costs. |
63 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
64 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
65 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
66 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
67 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
January 3, 2026 | December 28, 2024 | ||
Raw Materials | $ | $ | |
Work in Progress | |||
Finished goods | |||
$ | $ |
January 3, 2026 | December 28, 2024 | ||
Finished beds, including deliveries in-transit to those customers who have utilized home delivery services | $ | $ | |
Finished components that were ready for assembly for the completion of beds | |||
Retail accessories | |||
$ | $ |
January 3, 2026 | December 28, 2024 | ||
Leasehold improvements | $ | $ | |
Furniture and equipment | |||
Production machinery, computer equipment and software | |||
Construction in progress | |||
Less: Accumulated depreciation and amortization | ( | ( | |
$ | $ |
68 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
January 3, 2026 | December 28, 2024 | ||||||
Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization | ||||
Developed technologies | $ | $ | $ | $ | |||
Patents | |||||||
$ | $ | $ | $ | ||||
2026 | $ |
2027 | |
2028 | |
2029 | |
2030 | |
Total future amortization for definite-lived intangible assets | $ |
January 3, 2026 | December 28, 2024 | ||
Outstanding borrowings | $ | $ | |
Outstanding letters of credit | $ | $ | |
Additional borrowing capacity | $ | $ | |
Weighted-average interest rate |
69 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
70 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | 2023 | |||
Operating lease costs(1) | $ | $ | $ | ||
Variable lease costs(2) | $ | $ | $ |
2026 | $ |
2027 | |
2028 | |
2029 | |
2030 | |
Thereafter | |
Total operating lease payments(2) | |
Less: Interest | |
Present value of operating lease liabilities | $ |
January 3, 2026 | December 28, 2024 | |||
Weighted-average remaining lease term (years) | ||||
Weighted-average discount rate |
(in thousands) | 2025 | 2024 | 2023 | |||
Cash paid for amounts included in present value of operating lease liabilities(1) | $ | $ | $ | |||
Right-of-use assets obtained in exchange for operating lease liabilities | $ | $ | $ |
2025 | 2024 | 2023 | |||
Stock awards(1) | $ | $ | $ | ||
Stock options | |||||
Total stock-based compensation expense(1) | $ | $ | $ |
71 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Stock Options | Weighted- Average Exercise Price per Share | Weighted- Average Remaining Contractual Term (years) | Aggregate Intrinsic Value(1) | ||||
Outstanding at December 28, 2024 | $ | $ | |||||
Granted | |||||||
Exercised | |||||||
Canceled/Forfeited | ( | ||||||
Outstanding at January 3, 2026 | $ | $ | |||||
Exercisable at January 3, 2026 | $ | $ | |||||
Vested and expected to vest at January 3, 2026 | $ | $ |
2025 | 2024 | 2023 | |||
Weighted-average grant date fair value of stock options granted | $ | $ | $ | ||
Total intrinsic value (at exercise) of stock options exercised | $ | $ | $ |
Valuation Assumptions | 2025 | 2024 | 2023 | ||
Expected dividend yield | |||||
Expected volatility | |||||
Risk-free interest rate | |||||
Expected term (years) | — | — |
72 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Time- Based Stock Awards | Weighted- Average Grant Date Fair Value | Performance- Based Stock Awards | Weighted- Average Grant Date Fair Value | ||||
Outstanding at December 28, 2024 | $ | $ | |||||
Granted | |||||||
Vested | ( | ||||||
Canceled/Forfeited | ( | ( | |||||
Outstanding at January 3, 2026 | $ | $ |
2025 | 2024 | 2023 | |||
Amount repurchased under Board-approved share repurchase program | $ | $ | $ | ||
Amount repurchased in connection with the vesting of employee restricted stock grants | |||||
Total amount repurchased (based on trade dates) | $ | $ | $ |
2025 | 2024 | 2023 | |||
Net loss | $( | $( | $( | ||
Reconciliation of weighted-average shares outstanding: | |||||
Basic weighted-average shares outstanding | |||||
Dilutive effect of stock-based awards | |||||
Diluted weighted-average shares outstanding | |||||
Net loss per share – basic and diluted | $( | $( | $( |
73 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
January 3, 2026 | December 28, 2024 | ||
Deferred contract assets included in: | |||
Other current assets | $ | $ | |
Other non-current assets | |||
$ | $ |
January 3, 2026 | December 28, 2024 | ||
Deferred contract liabilities included in: | |||
Other current liabilities | $ | $ | |
Other non-current liabilities | |||
$ | $ |
2025 | 2024 | 2023 | |||
Retail stores | $ | $ | $ | ||
Online, phone, chat and other | |||||
Total Company | $ | $ | $ |
2025 | 2024 | ||
Balance at beginning of year | $ | $ | |
Additions that reduce net sales | |||
Deduction from reserves | ( | ( | |
Balance at end of period | $ | $ |
74 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | ||||
Cash restructuring costs: | |||||
Contract termination costs(1) | $ | $ | |||
Severance and employee-related benefits | |||||
Professional fees and other | |||||
Total cash restructuring costs | |||||
Non-cash restructuring costs: | |||||
Asset impairments(2) | |||||
Total restructuring costs | $ | $ |
2025 | 2024 | ||||
Balance at December 28,2024 | $ | $ | |||
Expenses | |||||
Cash payments | ( | ( | |||
Balance at January 3, 2026 | $ | $ |
75 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Cumulative | ||||
January 3, 2026 | ||||
Cash restructuring costs: | ||||
Contract termination costs (1) | $ | |||
Severance and employee-related benefits | ||||
Professional fees and other | ||||
Total cash restructuring costs | ||||
Non-cash restructuring costs: | ||||
Asset impairments (2) | ||||
Total restructuring costs | $ |
2025 | 2024 | 2023 | |||
Current: | |||||
Federal | $ | $ | $ | ||
State | |||||
Deferred: | |||||
Federal | ( | ( | |||
State | ( | ( | |||
( | ( | ||||
Income tax expense (benefit) | $ | $( | $( |
76 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | ||
Statutory federal income tax | $( | |
State and local income taxes(1) | ||
State and local income taxes | ( | |
Changes in valuation allowance | ( | |
Tax credits - research and development tax credit | ( | |
Changes in valuation allowance | ( | |
Nontaxable or nondeductible items | ||
Stock-based compensation | ( | |
Other | ( | |
Changes in unrecognized tax benefits | ( | |
Other | ( | |
Effective income tax | $ | ( |
2024 | 2023 | |||
Statutory federal income tax | ||||
State income taxes, net of federal benefit | ( | |||
R&D tax credits | ||||
Return to provision | ||||
Investment tax credit | ||||
Stock-based compensation | ( | ( | ||
Non-deductible compensation | ( | ( | ||
Non-deductible expenses | ( | ( | ||
Changes in unrecognized tax benefits | ( | ( | ||
Valuation allowance | ( | |||
Other | ( | |||
Effective income tax rate |
77 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | ||
Deferred tax assets: | |||
Stock-based compensation | $ | $ | |
Operating lease liabilities | |||
Warranty and returns liabilities | |||
Net operating loss carryforwards and credits | |||
Compensation and benefits | |||
Research and development | |||
Interest | |||
Other | |||
Total gross deferred tax assets | |||
Valuation allowance | ( | ( | |
Total gross deferred tax assets after valuation allowance | |||
Deferred tax liabilities: | |||
Property and equipment | |||
Operating lease right-of-use assets | |||
Deferred revenue | |||
Other | |||
Total gross deferred tax liabilities | |||
Net deferred tax assets | $ | $ |
78 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | |
Cash paid for income taxes, net: | |
Federal | $ |
State and local | |
Texas | |
Illinois | |
Other | |
Total cash paid for income taxes, net: | $ |
Federal and State Tax | |||||
2025 | 2024 | 2023 | |||
Beginning balance | $ | $ | $ | ||
Increases related to current-year tax positions | |||||
Increases related to prior-year tax positions | |||||
Decreases related to prior-year tax positions | ( | ||||
Lapse of statute of limitations | ( | ( | ( | ||
Settlements with taxing authorities | ( | ||||
Ending balance | $ | $ | $ | ||
79 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
2025 | 2024 | 2023 | |||
Net Sales | $ | $ | $ | ||
Less: | |||||
Cost of sales | ( | ( | ( | ||
Marketing expenses | ( | ( | ( | ||
Selling expenses | ( | ( | ( | ||
General and administrative | ( | ( | ( | ||
Research and development | ( | ( | ( | ||
Restructuring costs | ( | ( | ( | ||
Asset impairment charges | ( | ( | |||
Interest expense | ( | ( | ( | ||
Income tax (expense) benefit | ( | ||||
Net loss | $( | $( | $( |
80 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
81 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
82 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
83 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
84 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Exhibit No. | Description | ||
3.1 | |||
3.2 | |||
3.3 | |||
3.4 | |||
3.5 | |||
4.1 | |||
10.1 | |||
10.2 | |||
10.3 | |||
10.4 | |||
10.5 | |||
10.6 | |||
10.7 | |||
10.8 |
85 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Exhibit No. | Description | ||
10.9 | |||
10.10* | |||
10.11† | |||
10.12† | |||
10.13† | |||
10.14† | |||
10.15† | |||
10.16†* | |||
10.17† | |||
10.18† | |||
10.19† | |||
10.20† | |||
10.21† | |||
10.22† | |||
10.23† |
86 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Exhibit No. | Description | ||
10.24† | |||
10.25† | |||
10.26† | |||
10.27 | |||
10.28 | |||
10.29 | |||
10.30 | |||
10.31 | |||
10.32 | |||
10.33 | |||
10.34 | |||
10.35† | |||
10.36† |
87 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Exhibit No. | Description | ||
10.37† | |||
10.38† | |||
10.39† | |||
10.40† | |||
10.41† | |||
10.42† | |||
10.43† | |||
10.44† | |||
10.45† | |||
10.46† | |||
10.47† | |||
10.48† | |||
10.49† | |||
10.50† |
88 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Exhibit No. | Description | ||
10.51† | |||
10.52† | |||
10.53† | |||
10.54† | |||
10.55† | |||
10.56† | |||
10.57†* | |||
19.1* | |||
21.1 | |||
23.1* | |||
24.1* | |||
31.1* | |||
31.2* | |||
32.1* | |||
32.2* | |||
97.1† | |||
101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | ||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | ||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | ||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||
104* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
89 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
90 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
SLEEP NUMBER CORPORATION | |||
(Registrant) | |||
March 12, 2026 | By: | /s/ Linda Findley | |
Linda Findley | |||
President and Chief Executive Officer | |||
(principal executive officer) | |||
By: | /s/ Amy K. O’Keefe | ||
Amy K. O’Keefe | |||
Chief Financial Officer | |||
(principal financial officer) | |||
By: | /s/ Kelly F. Baker | ||
Kelly F. Baker | |||
Principal Accounting Officer | |||
(principal accounting officer) | |||
91 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Name | Title | Date | ||
/s/ Phillip M. Eyler | Chair of the Board | March 10, 2026 | ||
Phillip M. Eyler | ||||
/s/ Linda A. Findley | Director | March 11, 2026 | ||
Linda A. Findley | ||||
/s/ Julie M. Howard | Director | March 11, 2026 | ||
Julie M. Howard | ||||
/s/ Deborah L. Kilpatrick | Director | March 10, 2026 | ||
Deborah L. Kilpatrick | ||||
/s/ Stephen E. Macadam | Director | March 11, 2026 | ||
Stephen E. Macadam | ||||
/s/ Angel L. Mendez | Director | March 10, 2026 | ||
Angel L. Mendez | ||||
/s/ Hilary A. Schneider | Director | March 11, 2026 | ||
Hilary A. Schneider |
92 | 2025 FORM 10-K | SLEEP NUMBER CORPORATION | |
Description | 2025 | 2024 | 2023 | |||
Allowances for credit losses | ||||||
Balance at beginning of period | $ | $ | $ | |||
Additions charged to costs and expenses | ||||||
Deductions from reserves | ( | ( | ( | |||
Balance at end of period | $ | $ | $ |